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Abstract: Genome-wide associa-
tion studies (GWAS) have evolved
over the last ten years into a
powerful tool for investigating the
genetic architecture of human dis-
ease. In this work, we review the
key concepts underlying GWAS,
including the architecture of com-
mon diseases, the structure of
common human genetic variation,
technologies for capturing genetic
information, study designs, and the
statistical methods used for data
analysis. We also look forward to
the future beyond GWAS.
This article is part of the ‘‘Transla-
tional Bioinformatics’’ collection for
PLOS Computational Biology.
1. Important Questions in
Human Genetics
A central goal of human genetics is to
identify genetic risk factors for common,
complex diseases such as schizophrenia
and type II diabetes, and for rare Mende-
lian diseases such as cystic fibrosis and
sickle cell anemia. There are many
different technologies, study designs and
analytical tools for identifying genetic risk
factors. We will focus here on the genome-
wide association study or GWAS that
measures and analyzes DNA sequence
variations from across the human genome
in an effort to identify genetic risk factors
for diseases that are common in the
population. The ultimate goal of GWAS
is to use genetic risk factors to make
predictions about who is at risk and to
identify the biological underpinnings of
disease susceptibility for developing new
prevention and treatment strategies. One
of the early successes of GWAS was the
identification of the Complement Factor H
gene as a major risk factor for age-related
macular degeneration or AMD [1–3]. Not
only were DNA sequence variations in this
gene associated with AMD but the bio-
logical basis for the effect was demonstrat-
ed. Understanding the biological basis of
genetic effects will play an important role in
developing new pharmacologic therapies.
While understanding the complexity of
human health and disease is an important
objective, it is not the only focus of human
genetics. Accordingly, one of the most
successful applications of GWAS has been
in the area of pharmacology. Pharmaco-
genetics has the goal of identifying DNA
sequence variations that are associated
with drug metabolism and efficacy as well
as adverse effects. For example, warfarin is
a blood-thinning drug that helps prevent
blood clots in patients. Determining the
appropriate dose for each patient is
important and believed to be partly
controlled by genes. A recent GWAS
revealed DNA sequence variations in
several genes that have a large influence
on warfarin dosing [4]. These results, and
more recent validation studies, have led to
genetic tests for warfarin dosing that can
be used in a clinical setting. This type of
genetic test has given rise to a new field
called personalized medicine that aims to
tailor healthcare to individual patients
based on their genetic background and
other biological features. The widespread
availability of low-cost technology for
measuring an individual’s genetic back-
ground has been harnessed by businesses
that are now marketing genetic testing
directly to the consumer. Genome-wide
association studies, for better or for worse,
have ushered in the exciting era of
personalized medicine and personal ge-
netic testing. The goal of this chapter is to
introduce and review GWAS technology,
study design and analytical strategies as an
important example of translational bioin-
formatics. We focus here on the application
of GWAS to common diseases that have a
complex multifactorial etiology.




The modern unit of genetic variation is
the single nucleotide polymorphism or SNP.
SNPs are single base-pair changes in the
DNA sequence that occur with high
frequency in the human genome [5]. For
the purposes of genetic studies, SNPs are
typically used as markers of a genomic
region, with the large majority of them
having a minimal impact on biological
systems. SNPs can have functional conse-
quences, however, causing amino acid
changes, changes to mRNA transcript
stability, and changes to transcription
factor binding affinity [6]. SNPs are by
far the most abundant form of genetic
variation in the human genome.
SNPs are notably a type of common
genetic variation; many SNPs are present
in a large proportion of human popula-
tions [7]. SNPs typically have two alleles,
meaning within a population there are
two commonly occurring base-pair pos-
sibilities for a SNP location. The fre-
quency of a SNP is given in terms of the
minor allele frequency or the frequency of
the less common allele. For example, a
SNP with a minor allele (G) frequency of
0.40 implies that 40% of a population
has the G allele versus the more common
allele (the major allele), which is found in
60% of the population.
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Commonly occurring SNPs lie in stark
contrast to genetic variants that are
implicated in more rare genetic disorders,
such as cystic fibrosis [8]. These conditions
are largely caused by extremely rare
genetic variants that ultimately induce a
detrimental change to protein function,
which leads to the disease state. Variants
with such low frequency in the population
are sometimes referred to as mutations,
though they can be structurally equivalent
to SNPs - single base-pair changes in the
DNA sequence. In the genetics literature,
the term SNP is generally applied to
common single base-pair changes, and the
term mutation is applied to rare genetic
variants.
2.2 Failures of Linkage for Complex
Disease
Cystic fibrosis (and most rare genetic
disorders) can be caused by multiple
different genetic variants within a single
gene. Because the effect of the genetic
variants is so strong, cystic fibrosis follows
an autosomal dominant inheritance pat-
tern in families with the disorder. One of
the major successes of human genetics was
the identification of multiple mutations in
the CFTR gene as the cause of cystic
fibrosis [8]. This was achieved by geno-
typing families affected by cystic fibrosis
using a collection of genetic markers across
the genome, and examining how those
genetic markers segregate with the disease
across multiple families. This technique,
called linkage analysis, was subsequently
applied successfully to identify genetic
variants that contribute to rare disorders
like Huntington disease [9]. When applied
to more common disorders, like heart
disease or various forms of cancer, linkage
analysis has not fared as well. This implies
the genetic mechanisms that influence
common disorders are different from those
that cause rare disorders [10].
2.3 Common Disease Common
Variant Hypothesis
The idea that common diseases have a
different underlying genetic architecture
than rare disorders, coupled with the
discovery of several susceptibility variants
for common disease with high minor allele
frequency (including alleles in the apolipo-
protein E or APOE gene for Alzheimer’s
disease [11] and PPARg gene in type II
diabetes [12]), led to the development of
the common disease/common variant (CD/CV)
hypothesis [13].
This hypothesis states simply that com-
mon disorders are likely influenced by
genetic variation that is also common in
the population. There are several key
ramifications of this for the study of
complex disease. First, if common genetic
variants influence disease, the effect size
(or penetrance) for any one variant must
be small relative to that found for rare
disorders. For example, if a SNP with 40%
frequency in the population causes a
highly deleterious amino acid substitution
that directly leads to a disease phenotype,
nearly 40% of the population would have
that phenotype. Thus, the allele frequency
and the population prevalence are com-
pletely correlated. If, however, that same
SNP caused a small change in gene
expression that alters risk for a disease by
some small amount, the prevalence of the
disease and the influential allele would be
only slightly correlated. As such, common
variants almost by definition cannot have
high penetrance.
Secondly, if common alleles have small
genetic effects (low penetrance), but com-
mon disorders show heritability (inheri-
tance in families), then multiple common
alleles must influence disease susceptibility.
For example, twin studies might estimate
the heritability of a common disease to be
40%, that is, 40% of the total variance in
disease risk is due to genetic factors. If the
allele of a single SNP incurs only a small
degree of disease risk, that SNP only
explains a small proportion of the total
variance due to genetic factors. As such,
the total genetic risk due to common
genetic variation must be spread across
multiple genetic factors. These two points
suggest that traditional family-based ge-
netic studies are not likely to be successful
for complex diseases, prompting a shift
toward population-based studies.
The frequency with which an allele
occurs in the population and the risk
incurred by that allele for complex diseases
are key components to consider when
planning a genetic study, impacting the
technology needed to gather genetic
information and the sample size needed
to discover statistically significant genetic
effects. The spectrum of potential genetic
effects is sometimes visualized and parti-
tioned by effect size and allele frequency
(figure 1). Genetic effects in the upper right
are more amenable to smaller family-
based studies and linkage analysis, and
may require genotyping relatively few
genetic markers. Effects in the lower right
are typical of findings from GWAS,
requiring large sample sizes and a large
panel of genetic markers. Effects in the
upper right, most notably CFH, have been
identified using both linkage analysis and
GWAS. Effects in the lower left are
perhaps the most difficult challenge, re-
quiring genomic sequencing of large
samples to associate rare variants to
disease.
Over the last five years, the common
disease/common variant hypothesis has
been tested for a variety of common
diseases, and while much of the heritability
for these conditions is not yet explained,
common alleles certainly play a role in
susceptibility. The National Human Ge-
nome Institute GWAS catalog (http://
www.genome.gov/gwastudies) lists over
3,600 SNPs identified for common diseas-
es or traits, and in general, common
diseases have multiple susceptibility alleles,
each with small effect sizes (typically
increasing disease risk between 1.2–2
times the population risk) [14]. From these
results we can say that for most common
diseases, the CD/CV hypothesis is true,
though it should not be assumed that the
entire genetic component of any common
disease is due to common alleles only.
3. Capturing Common Variation
3.1 The Human Haplotype Map
Project
To test the common disease/common
variant hypothesis for a phenotype, a
systematic approach is needed to interro-
gate much of the common variation in the
human genome. First, the location and
density of commonly occurring SNPs is
needed to identify the genomic regions
and individual sites that must be examined
by genetic studies. Secondly, population-
specific differences in genetic variation
must be cataloged so that studies of
phenotypes in different populations can
be conducted with the proper design.
Finally, correlations among common ge-
netic variants must be determined so that
genetic studies do not collect redundant
information. The International HapMap
Project was designed to identify variation
What to Learn in This Chapter
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across the genome and to characterize
correlations among variants.
The International HapMap Project
used a variety of sequencing techniques
to discover and catalog SNPs in European
descent populations, the Yoruba popula-
tion of African origin, Han Chinese
individuals from Beijing, and Japanese
individuals from Tokyo [15,16]. The
project has since been expanded to include
11 human populations, with genotypes for
1.6 million SNPs [7]. HapMap genotype
data allowed the examination of linkage
disequilibrium.
3.2 Linkage Disequilibrium
Linkage disequilibrium (LD) is a prop-
erty of SNPs on a contiguous stretch of
genomic sequence that describes the
degree to which an allele of one SNP is
inherited or correlated with an allele of
another SNP within a population. The
term linkage disequilibrium was coined by
population geneticists in an attempt to
mathematically describe changes in ge-
netic variation within a population over
time. It is related to the concept of
chromosomal linkage, where two markers on
a chromosome remain physically joined
on a chromosome through generations of
a family. In figure 2, two founder
chromosomes are shown (one in blue
and one in orange). Recombination
events within a family from generation
to generation break apart chromosomal
segments. This effect is amplified through
generations, and in a population of fixed
size undergoing random mating, repeated
random recombination events will break
apart segments of contiguous chromo-
some (containing linked alleles) until
eventually all alleles in the population
are in linkage equilibrium or are indepen-
dent. Thus, linkage between markers on a
population scale is referred to as linkage
disequilibrium.
The rate of LD decay is dependent on
multiple factors, including the population
size, the number of founding chromo-
somes in the population, and the number
of generations for which the population
has existed. As such, different human sub-
populations have different degrees and
patterns of LD. African-descent popula-
tions are the most ancestral and have
smaller regions of LD due to the accumu-
lation of more recombination events in
that group. European-descent and Asian-
descent populations were created by
founder events (a sampling of chromo-
somes from the African population), which
altered the number of founding chromo-
somes, the population size, and the
generational age of the population. These
populations on average have larger regions
of LD than African-descent groups.
Many measures of LD have been
proposed [17], though all are ultimately
related to the difference between the
observed frequency of co-occurrence for
two alleles (i.e. a two-marker haplotype)
and the frequency expected if the two
markers are independent. The two com-
monly used measures of linkage disequi-
librium are D’ and r2 [15,17] shown in
equations 1 and 2. In these equations, p12
is the frequency of the ab haplotype, p1: is
Figure 1. Spectrum of Disease Allele Effects. Disease associations are often conceptualized in two dimensions: allele frequency and effect size.
Highly penetrant alleles for Mendelian disorders are extremely rare with large effect sizes (upper left), while most GWAS findings are associations of
common SNPs with small effect sizes (lower right). The bulk of discovered genetic associations lie on the diagonal denoted by the dashed lines.
doi:10.1371/journal.pcbi.1002822.g001
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the frequency of the a allele, and p2: is the


















D’ is a population genetics measure that is
related to recombination events between
markers and is scaled between 0 and 1. A
D’ value of 0 indicates complete linkage
equilibrium, which implies frequent re-
combination between the two markers and
statistical independence under principles
of Hardy-Weinberg equilibrium. A D’ of 1
indicates complete LD, indicating no
recombination between the two markers
within the population. For the purposes of
genetic analysis, LD is generally reported
in terms of r2, a statistical measure of
correlation. High r2 values indicate that
two SNPs convey similar information, as
one allele of the first SNP is often observed
with one allele of the second SNP, so only
one of the two SNPs needs to be
genotyped to capture the allelic variation.
There are dependencies between these
two statistics; r2 is sensitive to the allele
frequencies of the tow markers, and can
only be high in regions of high D’.
One often forgotten issue associated
with LD measures is that current technol-
ogy does not allow direct measurement of
haplotype frequencies from a sample
because each SNP is genotyped indepen-
dently and the phase or chromosome of
origin for each allele is unknown. Many
well-developed and documented methods
for inferring haplotype phase and estimat-
ing the subsequent two-marker haplotype
frequencies exist, and generally lead to
reasonable results [18].
SNPs that are selected specifically to
capture the variation at nearby sites in the
genome are called tag SNPs because alleles
for these SNPs tag the surrounding stretch
of LD. As noted before, patterns of LD are
population specific and as such, tag SNPs
selected for one population may not work
well for a different population. LD is
exploited to optimize genetic studies,
preventing genotyping SNPs that provide
redundant information. Based on analy-
sis of data from the HapMap project,
.80% of commonly occurring SNPs in
European descent populations can be
captured using a subset of 500,000 to one
million SNPs scattered across the ge-
nome [19].
3.3 Indirect Association
The presence of LD creates two possible
positive outcomes from a genetic associa-
tion study. In the first outcome, the SNP
influencing a biological system that ulti-
mately leads to the phenotype is directly
genotyped in the study and found to be
statistically associated with the trait. This is
referred to as a direct association, and the
genotyped SNP is sometimes referred to as
the functional SNP. The second possibility is
that the influential SNP is not directly
typed, but instead a tag SNP in high LD
with the influential SNP is typed and
statistically associated to the phenotype
(figure 3). This is referred to as an indirect
association [10]. Because of these two
possibilities, a significant SNP association
from a GWAS should not be assumed as
the causal variant and may require
Figure 2. Linkage and Linkage Disequilibrium. Within a family, linkage occurs when two genetic markers (points on a chromosome) remain
linked on a chromosome rather than being broken apart by recombination events during meiosis, shown as red lines. In a population, contiguous
stretches of founder chromosomes from the initial generation are sequentially reduced in size by recombination events. Over time, a pair of markers
or points on a chromosome in the population move from linkage disequilibrium to linkage equilibrium, as recombination events eventually occur
between every possible point on the chromosome.
doi:10.1371/journal.pcbi.1002822.g002
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additional studies to map the precise
location of the influential SNP.
Conceptually, the end result of GWAS
under the common disease/common var-
iant hypothesis is that a panel of 500,000
to one million markers will identify
common SNPs that are associated to
common phenotypes. To conduct such a
study practically requires a genotyping
technology that can accurately capture
the alleles of 500,000 to one million SNPs
for each individual in a study in a cost-
effective manner.
4. Genotyping Technologies
Genome-wide association studies were
made possible by the availability of chip-
based microarray technology for assaying
one million or more SNPs. Two primary
platforms have been used for most GWAS.
These include products from Illumina
(San Diego, CA) and Affymetrix (Santa
Clara, CA). These two competing tech-
nologies have been recently reviewed [20]
and offer different approaches to measure
SNP variation. For example, the Affyme-
trix platform prints short DNA sequences
as a spot on the chip that recognizes a
specific SNP allele. Alleles (i.e. nucleotides)
are detected by differential hybridization
of the sample DNA. Illumina on the other
hand uses a bead-based technology with
slightly longer DNA sequences to detect
alleles. The Illumina chips are more
expensive to make but provide better
specificity.
Aside from the technology, another
important consideration is the SNPs that
each platform has selected for assay. This
can be important depending on the
specific human population being studied.
For example, it is important to use a chip
that has more SNPs with better overall
genomic coverage for a study of Africans
than Europeans. This is because African
genomes have had more time to recom-
bine and therefore have less LD between
alleles at different SNPs. More SNPs are
needed to capture the variation across the
African genome.
It is important to note that the technol-
ogy for measuring genomic variation is
changing rapidly. Chip-based genotyping
platforms such as those briefly mentioned
above will likely be replaced over the next
few years with inexpensive new technolo-
gies for sequencing the entire genome.
These next-generation sequencing meth-
ods will provide all the DNA sequence
variation in the genome. It is time now to
retool for this new onslaught of data.
5. Study Design
Regardless of assumptions about the
genetic model of a trait, or the technology
used to assess genetic variation, no genetic
study will have meaningful results without
a thoughtful approach to characterize the
phenotype of interest. When embarking
on a genetic study, the initial focus should
be on identifying precisely what quantity or
trait genetic variation influences.
5.1 Case Control versus Quantitative
Designs
There are two primary classes of
phenotypes: categorical (often binary
case/control) or quantitative. From the
statistical perspective, quantitative traits
are preferred because they improve power
to detect a genetic effect, and often have a
more interpretable outcome. For some
disease traits of interest, quantitative
disease risk factors have already been
identified. High-density lipoprotein
(HDL) and low-density lipoprotein (LDL)
cholesterol levels are strong predictors of
heart disease, and so genetic studies of
heart disease outcomes can be conducted
by examining these levels as a quantitative
trait. Assays for HDL and LDL levels,
being already useful for clinical practice,
are precise and ubiquitous measurements
that are easy to obtain. Genetic variants
that influence these levels have a clear
interpretation – for example, a unit
change in LDL level per allele or by
genotype class. With an easily measurable
ubiquitous quantitative trait, GWAS of
blood lipids have been conducted in
numerous cohort studies. Their results
were also easily combined to conduct an
extremely well-powered massive meta-
analysis, which revealed 95 loci associated
to lipid traits in more than 100,000 people
[21]. Here, HDL and LDL may be the
primary traits of interest or can be
considered intermediate quantitative traits
or endophenotypes for cardiovascular
disease.
Other disease traits do not have well-
established quantitative measures. In these
circumstances, individuals are usually clas-
sified as either affected or unaffected – a
binary categorical variable. Consider the
vast difference in measurement error
associated with classifying individuals as
either ‘‘case’’ or ‘‘control’’ versus precisely
measuring a quantitative trait. For exam-
ple, multiple sclerosis is a complex clinical
phenotype that is often diagnosed over a
long period of time by ruling out other
possible conditions. However, despite the
‘‘loose’’ classification of case and control,
GWAS of multiple sclerosis have been
enormously successful, implicating more
than 10 new genes for the disorder [22].
So while quantitative outcomes are pre-
ferred, they are not required for a
successful study.
5.2 Standardized Phenotype Criteria
A major component of the success with
multiple sclerosis and other well-conduct-
ed case/control studies is the definition of
rigorous phenotype criteria, usually pre-
sented as rule list based on clinical
variables. Multiple sclerosis studies often
use the McDonald criteria for establishing
case/control status and defining clinical
subtypes [23]. Standardized methods like
the McDonald criteria establish a concise,
evidence-based approach that can be
uniformly applied by multiple diagnosing
clinicians to ensure that consistent pheno-
Figure 3. Indirect Association. Genotyped SNPs often lie in a region of high linkage disequilibrium with an influential allele. The genotyped SNP
will be statistically associated with disease as a surrogate for the disease SNP through an indirect association.
doi:10.1371/journal.pcbi.1002822.g003
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type definitions are used for a genetic
study.
Standardized phenotype rules are par-
ticularly critical for multi-center studies
to prevent introducing a site-based effect
into the study. And even when estab-
lished phenotype criteria are used, there
may be variability among clinicians in
how those criteria are used to assign
case/control status. Furthermore, some
quantitative traits are susceptible to bias
in measurement. For example, with
cataract severity lens photographs are
used to assign cases to one of three types
of lens opacity. In situations where there
may be disagreement among clinicians, a
subset of study records is often examined
by clinicians at multiple centers to assess
interrater agreement as a measure of
phenotyping consistency [24]. High in-
terrater agreement means that phenotype
rules are being consistently applied across
multiple sites, whereas low agreement
suggests that criteria are not uniformly
interpreted or applied, and may indicate
a need to establish more narrow pheno-
type criteria.
5.3 Phenotype Extraction from
Electronic Medical Records
The last few years of genetic research
has seen the growth of large clinical bio-
repositories that are linked to electronic
medical records (EMRs) [25]. The devel-
opment of these resources will certainly
advance the state of human genetics
research and foster integration of genetic
information into clinical practice. From a
study design perspective, identifying phe-
notypes from EMRs can be challenging.
Electronic medical records were estab-
lished for clinical care and administrative
purposes – not for research. As such,
idiosyncrasies arise due to billing practices
and other logistical reasons, and great care
must be taken not to introduce biases into
a genetic study.
The established methodology for con-
ducting ‘‘electronic phenotyping’’ is to
devise an initial selection algorithm
(using structured EMR fields, such as
billing codes, or text mining procedures
on unstructured text), which identifies a
record subset from the bio-repository. In
cases where free text is parsed, natural
language processing (NLP) is used in
conjunction with a controlled vocabulary
such as the Unified Medical Language
System (UMLS) to relate text to more
structured and uniform medical con-
cepts. In some instances, billing codes
alone may be sufficient to accurately
identify individuals with a particular
phenotype, but often combinations of
billing and procedure codes, along with
free text are necessary. Because every
medical center has its own set of policies,
care providers, and health insurance
providers, some algorithms developed in
one clinical setting may not work as well
in another.
Once a manageable subset of records is
obtained by an algorithm, the accuracy of
the results is examined by clinicians or
other phenotype experts as gold-standard
for comparison. The positive predictive
value (PPV) of the initial algorithm is
assessed, and based on feedback from case
reviewers, the selection algorithm is re-
fined. This process of case-review followed
by algorithmic refinement is continued
until the desired PPV is reached.
This approach has been validated by
replicating established genotype-pheno-
type relationships using EMR-derived
phenotypes [16], and has been applied to
multiple clinical and pharmacogenomic
conditions [26–28].
6. Association Test
6.1 Single Locus Analysis
When a well-defined phenotype has
been selected for a study population, and
genotypes are collected using sound tech-
niques, the statistical analysis of genetic
data can begin. The de facto analysis of
genome-wide association data is a series of
single-locus statistic tests, examining each
SNP independently for association to the
phenotype. The statistical test conducted
depends on a variety of factors, but first
and foremost, statistical tests are different
for quantitative traits versus case/control
studies.
Quantitative traits are generally ana-
lyzed using generalized linear model (GLM)
approaches, most commonly the Analysis
of Variance (ANOVA), which is similar to
linear regression with a categorical pre-
dictor variable, in this case genotype
classes. The null hypothesis of an ANOVA
using a single SNP is that there is no
difference between the trait means of any
genotype group. The assumptions of GLM
and ANOVA are 1) the trait is normally
distributed; 2) the trait variance within
each group is the same (the groups are
homoskedastic); 3) the groups are inde-
pendent.
Dichotomous case/control traits are
generally analyzed using either contingen-
cy table methods or logistic regression.
Contingency table tests examine and
measure the deviation from independence
that is expected under the null hypothesis
that there is no association between the
phenotype and genotype classes. The most
ubiquitous form of this test is the popular
chi-square test (and the related Fisher’s
exact test).
Logistic regression is an extension of
linear regression where the outcome of a
linear model is transformed using a
logistic function that predicts the proba-
bility of having case status given a
genotype class. Logistic regression is often
the preferred approach because it allows
for adjustment for clinical covariates (and
other factors), and can provide adjusted
odds ratios as a measure of effect size.
Logistic regression has been extensively
developed, and numerous diagnostic pro-
cedures are available to aid interpretation
of the model.
For both quantitative and dichotomous
trait analysis (regardless of the analysis
method), there are a variety of ways that
genotype data can be encoded or shaped
for association tests. The choice of data
encoding can have implications for the
statistical power of a test, as the degrees of
freedom for the test may change depend-
ing on the number of genotype-based
groups that are formed. Allelic association
tests examine the association between one
allele of the SNP and the phenotype.
Genotypic association tests examine the
association between genotypes (or geno-
type classes) and the phenotype. The
genotypes for a SNP can also be grouped
into genotype classes or models, such as
dominant, recessive, multiplicative, or
additive models [29].
Each model makes different assump-
tions about the genetic effect in the data –
assuming two alleles for a SNP, A and a,
a dominant model (for A) assumes that
having one or more copies of the A allele
increases risk compared to a (i.e. Aa or
AA genotypes have higher risk). The
recessive model (for A) assumes that two
copies of the A allele are required to alter
risk, so individuals with the AA genotype
are compared to individuals with Aa and
aa genotypes. The multiplicative model
(for A) assumes that if there is 36 risk for
having a single A allele, there is a 96 risk
for having two copies of the A allele: in
this case if the risk for Aa is k, the risk for
AA is k2. The additive model (for A)
assumes that there is a uniform, linear
increase in risk for each copy of the A
allele, so if the risk is 36 for Aa, there is a
66 risk for AA - in this case the risk for
Aa is k and the risk for AA is 2k. A
common practice for GWAS is to exam-
ine additive models only, as the additive
model has reasonable power to detect
both additive and dominant effects, but it
is important to note that an additive
model may be underpowered to detect
some recessive effects [30]. Rather than
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choosing one model a priori, some studies
evaluate multiple genetic models coupled
with an appropriate correction for multi-
ple testing.
6.2 Covariate Adjustment and
Population Stratification
In addition to selecting an encoding
scheme, statistical tests should be adjusted
for factors that are known to influence the
trait, such as sex, age, study site, and
known clinical covariates. Covariate ad-
justment reduces spurious associations due
to sampling artifacts or biases in study
design, but adjustment comes at the price
of using additional degrees of freedom
which may impact statistical power. One
of the more important covariates to
consider in genetic analysis is a measure
of population substructure. There are
often known differences in phenotype
prevalence due to ethnicity, and allele
frequencies are highly variable across
human subpopulations, meaning that in
a sample with multiple ethnicities, ethnic-
specific SNPs will likely be associated to
the trait due to population stratification.
To prevent population stratification, the
ancestry of each sample in the dataset is
measured using STRUCTURE [31] or
EIGENSTRAT [32] methods that com-
pare genome-wide allele frequencies to
those of HapMap ethnic groups. The
results of these analyses can be used to
either exclude samples with similarity to a
non-target population, or they can be used
as a covariate in association analysis.
EIGENSTRAT is commonly used in this
circumstance, where principle component
analysis is used to generate principle
component values that could be described
as an ‘‘ethnicity score’’. When used as
covariates, these scores adjust for minute
ancestry effects in the data.
6.3 Corrections for Multiple Testing
A p-value, which is the probability of
seeing a test statistic equal to or greater
than the observed test statistic if the null
hypothesis is true, is generated for each
statistical test. This effectively means that
lower p-values indicate that if there is no
association, the chance of seeing this result
is extremely small.
Statistical tests are generally called
significant and the null hypothesis is
rejected if the p-value falls below a
predefined alpha value, which is nearly
always set to 0.05. This means that 5% of
the time, the null hypothesis is rejected
when in fact it is true and we detect a false
positive. This probability is relative to a
single statistical test; in the case of
GWAS, hundreds of thousands to mil-
lions of tests are conducted, each one with
its own false positive probability. The
cumulative likelihood of finding one or
more false positives over the entire
GWAS analysis is therefore much higher.
For a somewhat morbid analogy, consider
the probability of having a car accident. If
you drive your car today, the probability
of having an accident is fairly low.
However if you drive every day for the
next five years, the probability of you
having one or more accidents over that
time is much higher than the probability
of having one today.
One of the simplest approaches to
correct for multiple testing is the Bonfer-
roni correction. The Bonferroni correction
adjusts the alpha value from a= 0.05 to
a= (0.05/k) where k is the number of
statistical tests conducted. For a typical
GWAS using 500,000 SNPs, statistical
significance of a SNP association would
be set at 1e-7. This correction is the most
conservative, as it assumes that each
association test of the 500,000 is indepen-
dent of all other tests – an assumption that
is generally untrue due to linkage disequi-
librium among GWAS markers.
An alternative to adjusting the false
positive rate (alpha) is to determine the
false discovery rate (FDR). The false
discovery rate is an estimate of the
proportion of significant results (usually
at alpha = 0.05) that are false positives.
Under the null hypothesis that there are
no true associations in a GWAS dataset, p-
values for association tests would follow a
uniform distribution (evenly distributed
from 0 to 1). Originally developed by
Benjamini and Hochberg, FDR proce-
dures essentially correct for this number of
expected false discoveries, providing an
estimate of the number of true results
among those called significant [33]. These
techniques have been widely applied to
GWAS and extended in a variety of ways
[34].
Permutation testing is another approach
for establishing significance in GWAS.
While somewhat computationally inten-
sive, permutation testing is a straightfor-
ward way to generate the empirical
distribution of test statistics for a given
dataset when the null hypothesis is true.
This is achieved by randomly reassigning
the phenotypes of each individual to
another individual in the dataset, effec-
tively breaking the genotype-phenotype
relationship of the dataset. Each random
reassignment of the data represents one
possible sampling of individuals under the
null hypothesis, and this process is repeat-
ed a predefined number of times N to
generate an empirical distribution with
resolution N, so a permutation procedure
with an N of 1000 gives an empirical p-
value within 1/1000th of a decimal place.
Several software packages have been
developed to perform permutation testing
for GWAS studies, including the popular
PLINK software [35], PRESTO [36], and
PERMORY [37].
Another commonly used approach is to
rely on the concept of genome-wide signifi-
cance. Based on the distribution of LD in
the genome for a specific population,
there are an ‘‘effective’’ number of
independent genomic regions, and thus
an effective number of statistical tests that
should be corrected for. For European-
descent populations, this threshold has
been estimated at 7.2e-8 [38]. This
reasonable approach should be used with
caution, however, as the only scenario
where this correction is appropriate is
when hypotheses are tested on the
genome scale. Candidate gene studies or
replication studies with a focused hypoth-
esis do not require correction to this level,
as the number of effective, independent
statistical tests is much, much lower than
what is assumed for genome-wide signif-
icance.
6.4 Multi-Locus Analysis
In addition to single-locus analyses,
genome-wide association studies provide
an enormous opportunity to examine
interactions among genetic variants
throughout the genome. Multi-locus analy-
sis, however, is not nearly as straightfor-
ward as conducting single-locus tests, and
presents numerous computational, statisti-
cal, and logistical challenges [39].
Because most GWAS genotype be-
tween 500,000 and one million SNPs,
examining all pair-wise combinations of
SNPs is a computationally intractable
approach, even for highly efficient algo-
rithms. One approach to this issue is to
reduce or filter the set of genotyped SNPs,
eliminating redundant information. A
simple and common way to filter SNPs
is to select a set of results from a single-
SNP analysis based on an arbitrary
significance threshold and exhaustively
evaluate interactions in that subset. This
can be perilous, however, as selecting
SNPs to analyze based on main effects
will prevent certain multi-locus models
from being detected – so called ‘‘purely
epistatic’’ models with statistically unde-
tectable marginal effects. With these
models, a large component of the herita-
bility is concentrated in the interaction
rather than in the main effects. In other
words, a specific combination of markers
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(and only the combination of markers)
incurs a significant change in disease risk.
The benefits of this analysis are that it
performs an unbiased analysis for inter-
actions within the selected set of SNPs. It
is also far more computationally and
statistically tractable than analyzing all
possible combinations of markers.
Another strategy is to restrict examina-
tion of SNP combinations to those that
fall within an established biological con-
text, such as a biochemical pathway or a
protein family. As these techniques rely
on electronic repositories of structured
biomedical knowledge, they generally
couple a bioinformatics engine that gen-
erates SNP-SNP combinations with a
statistical method that evaluates combi-
nations in the GWAS dataset. For exam-
ple, the Biofilter approach uses a variety
of public data sources with logistic
regression and multifactor dimensionality
reduction methods [40,41]. Similarly,
INTERSNP uses logistic regression, log-
linear, and contingency table approaches
to assess SNP-SNP interaction models
[42].
7. Replication and Meta-
Analysis
7.1 Statistical Replication
The gold standard for validation of any
genetic study is replication in an additional
independent sample. That said, there are a
variety of criteria involved in defining
‘‘replication’’ of a GWAS result. This was
the subject of an NHGRI working group,
which outlined several criteria for estab-
lishing a positive replication [43]. These
criteria are discussed in the following
paragraphs.
Replication studies should have suffi-
cient sample size to detect the effect of the
susceptibility allele. Often, the effects
identified in an initial GWAS suffer from
winner’s curse, where the detected effect is
likely stronger in the GWAS sample than
in the general population [44]. This means
that replication samples should ideally be
larger to account for the over-estimation of
effect size. With replication, it is important
for the study to be well-powered to identify
spuriously associated SNPs where the null
hypothesis is most likely true – in other
words, to confidently call the initial
GWAS result a false-positive.
Replication studies should be conducted
in an independent dataset drawn from the
same population as the GWAS, in an
attempt to confirm the effect in the GWAS
target population. Once an effect is
confirmed in the target population, other
populations may be sampled to determine
if the SNP has an ethnic-specific effect.
Replication of a significant result in an
additional population is sometimes re-
ferred to as generalization, meaning the
genetic effect is of general relevance to
multiple human populations.
Identical phenotype criteria should be
used in both GWAS and replication
studies. Replication of a GWAS result
should be thought of as the replication of a
specific statistical model – a given SNP
predicts a specific phenotype effect. Using
even slightly different phenotype defini-
tions between GWAS and replication
studies can cloud the interpretation of
the final result.
A similar effect should be seen in the
replication set from the same SNP, or a
SNP in high LD with the GWAS-identi-
fied SNP. Because GWAS typically use
SNPs that are markers that were chosen
based on LD patterns, it is difficult to say
what SNP within the larger genomic
region is mechanistically influencing dis-
ease risk. With this in mind, the unit of
replication for a GWAS should be the
genomic region, and all SNPs in high LD are
potential replication candidates. However,
continuity of effect should be demonstrat-
ed across both studies, with the magnitude
and direction of effect being similar for the
genomic region in both datasets. If SNPs
in high LD are used to demonstrate the
effect in replication, the direction of effect
must be determined using a reference
panel to determine two-SNP haplotype
frequencies. For example, if allele A is
associated in the GWAS with an odds
ratio of 1.5, and allele T of a nearby SNP
is associated in the replication set with an
odds ratio of 1.46, it must be demonstrated
that allele A and allele T carry effects in
the same direction. The most straightfor-
ward way to assess this is to examine a
reference panel, such as the HapMap
data, for a relevant population. If this
panel shows that allele A from SNP 1 and
allele T from SNP 2 form a two-marker
haplotype in 90% of the sample, then this
is a reasonable assumption. If however the
panel shows that allele A from SNP 1 and
allele A from SNP 2 form the predomi-
nant two-marker haplotype, the effect has
probably flipped in the replication set.
Mapping the effect through the haplotype
would be equivalent to observing an odds
ratio of 1.5 in the GWAS and 0.685 in the
replication set.
In brief, the general strategy for a
replication study is to repeat the ascertain-
ment and design of the GWAS as closely as
possible, but examine only specific genetic
effects found significant in the GWAS.
Effects that are consistent across the two
studies can be labeled replicated effects.
7.2 Meta-Analysis of Multiple
Analysis Results
The results of multiple GWAS studies
can be pooled together to perform a meta-
analysis. Meta-analysis techniques were
originally developed to examine and refine
significance and effect size estimates from
multiple studies examining the same hypothesis
in the published literature. With the
development of large academic consortia,
meta-analysis approaches allow the syn-
thesis of results from multiple studies
without requiring the transfer of protected
genotype or clinical information to parties
who were not part of the original study
approval – only statistical results from a
study need be transferred. For example, a
recent publication examining lipid profiles
was based on a meta-analysis of 46 studies
[21]. A study of this magnitude would be
logistically difficult (if not impossible)
without meta-analysis. Several software
packages are available to facilitate meta-
analysis, including STATA products and
METAL [45,46].
A fundamental principle in meta-anal-
ysis is that all studies included examined
the same hypothesis. As such, the general
design of each included study should be
similar, and the study-level SNP analysis
should follow near-identical procedures
across all studies (see Zeggini and Ioanni-
dis [47] for an excellent review). Quality
control procedures that determine which
SNPs are included from each site should
be standardized, along with any covariate
adjustments, and the measurement of
clinical covariates and phenotypes should
be consistent across multiple sites. The
sample sets across all studies should be
independent – an assumption that should
always be examined as investigators often
contribute the same samples to multiple
studies. Also, an extremely important and
somewhat bothersome logistical matter is
ensuring that all studies report results
relative to a common genomic build and
reference allele. If one study reports its
results relative to allele A and another
relative to allele B, the meta-analysis result
for this SNP may be non-significant
because the effects of the two studies
nullify each other.
With all of these factors to consider, it is
rare to find multiple studies that match
perfectly on all criteria. Therefore, study
heterogeneity is often statistically quantified
in a meta-analysis to determine the degree
to which studies differ. The most popular
measures of study heterogeneity are the Q
statistic and the I2 index [48], with the I2
index favored in more recent studies.
Coefficients resulting from a meta-analysis
have variability (or error) associated with
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them, and the I2 index represents the
approximate proportion of this variability
that can be attributed to heterogeneity
between studies [49]. I2 values fall into low
(,25), medium (.25 and ,75), and high
(.75) heterogeneity, and have been pro-
posed as a way to identify studies that
should perhaps be removed from a meta-
analysis. It is important to note that these
statistics should be used as a guide to
identifying studies that perhaps examine a
different underlying hypothesis than others
in the meta-analysis, much like outlier
analysis is used to identify unduly influential
points. Just as with outliers, however, a
study should only be excluded if there is an
obvious reason to do so based on the
parameters of the study – not simply
because a statistic indicates that this study
increases heterogeneity. Otherwise, agnos-
tic statistical procedures designed to reduce
meta-analysis heterogeneity will increase
false discoveries.
7.3 Data Imputation
To conduct a meta-analysis properly, the
effect of the same allele across multiple distinct
studies must be assessed. This can prove
difficult if different studies use different
genotyping platforms (which use different
SNP marker sets). As this is often the case,
GWAS datasets can be imputed to generate
results for a common set of SNPs across all
studies. Genotype imputation exploits
known LD patterns and haplotype frequen-
cies from the HapMap or 1000 Genomes
project to estimate genotypes for SNPs not
directly genotyped in the study [50].
The concept is similar in principle to
haplotype phasing algorithms, where the con-
tiguous set of alleles lying on a specific
chromosome is estimated. Genotype impu-
tation methods extend this idea to human
populations. First, a collection of shared
haplotypes within the study sample is
computed to estimate haplotype frequencies
among the genotyped SNPs. Phased haplo-
types from the study sample are compared
to reference haplotypes from a panel of
much more dense SNPs, such as the
HapMap data. The matched reference
haplotypes contain genotypes for surround-
ing markers that were not genotyped in the
study sample. Because the study sample
haplotypes may match multiple reference
haplotypes, surrounding genotypes may be
given a score or probability of a match based
on the haplotype overlap. For example,
rather than assign an imputed SNP a single
allele A, the probability of possible alleles is
reported (0.85 A, 0.12 C, 0.03 T ) based on
haplotype frequencies. This information can
be used in the analysis of imputed data to
take into account uncertainty in the geno-
type estimation process, typically using
Bayesian analysis approaches [51]. Popular
algorithms for genotype imputation include
BimBam [52], IMPUTE [53], MaCH [54],
and Beagle [55].
Much like conducting a meta-analysis,
genotype imputation must be conducted
with great care. The reference panel (i.e.
the 1000 Genomes data or the HapMap
project) must contain haplotypes drawn
from the same population as the study
sample in order to facilitate a proper
haplotype match. If a study was conducted
using individuals of Asian descent, but only
European descent populations are repre-
sented in the reference panel, the genotype
imputation quality will be poor as there is a
lower probability of a haplotype match.
Also, the reference allele for each SNP must
be identical in both the study sample and
the reference panel. Finally, the analysis of
imputed genotypes should account for the
uncertainty in genotype state generated by
the imputation process.
8. The Future
Genome-wide association studies have
had a huge impact on the field of human
genetics. They have identified new genet-
ic risk factors for many common human
diseases and have forced the genetics
community to think on a genome-wide
scale. On the horizon is whole-genome
sequencing. Within the next few years we
will see the arrival of cheap sequencing
technology that will replace one million
SNPs with the entire genomic sequence of
three billion nucleotides. Challenges asso-
ciated with data storage and manipula-
tion, quality control and data analysis will
be manifold more complex, thus chal-
lenging computer science and bioinfor-
matics infrastructure and expertise. Merg-
ing sequencing data with that from other
high-throughput technology for measur-
ing the transcriptome, the proteome, the
environment and phenotypes such as the
massive amounts of data that come from
neuroimaging will only serve to compli-
cate our goal to understand the genotype-
phenotype relationship for the purpose of
improving healthcare. Integrating these
many levels of complex biomedical data
along with their coupling with experi-
mental systems is the future of human
genetics.
9. Exercises
1. True or False: Common diseases, such
as type II diabetes and lung cancer, are
likely caused by mutations to a single
gene. Explain your answer.
2. Will the genotyping platforms designed
for GWAS of European Descent pop-
ulations be of equal utility in African
Descent populations? Why or why not?
3. When conducting a genetic study, what
additional factors should be measured
and adjusted for in the statistical
analysis?
4. True or False: SNPs that are associated
to disease using GWAS design should
be immediately considered for molec-
ular studies. Explain your answer.
Answers to the Exercises can be found
in Text S1.
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